Accepted for/Published in: JMIR Dermatology
Date Submitted: Nov 30, 2023
Open Peer Review Period: Dec 28, 2023 - Feb 22, 2024
Date Accepted: Aug 23, 2024
(closed for review but you can still tweet)
Warning: This is an author submission that is not peer-reviewed or edited. Preprints - unless they show as "accepted" - should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information.
Efficacy of ChatGPT in Educating Patients and Clinicians about Skin Toxicities of Cancer Treatment
ABSTRACT
This study investigates the application of ChatGPT, an artificial intelligence tool, in providing information on skin toxicities associated with cancer treatments. The study utilized 40 questions, split between patient-oriented and oncologist-oriented, to assess the accuracy and comprehensiveness of ChatGPT's responses. Three oncodermatology specialists from a New York tertiary academic institution evaluated the responses, which showed high accuracy and comprehensiveness. However, the reading level of the responses was at the college level, potentially limiting their accessibility to patients. The study highlighted that while ChatGPT can serve as a valuable resource for clinicians, its use for patient education requires careful consideration due to the complex nature of the information provided. There were also some concerns about the need for evidence-based and up-to-date clinical recommendations. Despite these challenges, ChatGPT demonstrates potential as a supplementary tool for oncologists and dermatologists in managing and educating about cancer treatment-related skin toxicities.
Citation
Request queued. Please wait while the file is being generated. It may take some time.
Copyright
© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.